These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 33629256)
41. Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers. Dyck JB; Maze M; Haack C; Azarnoff DL; Vuorilehto L; Shafer SL Anesthesiology; 1993 May; 78(5):821-8. PubMed ID: 8098191 [TBL] [Abstract][Full Text] [Related]
42. Non-linear pharmacokinetics of ofloxacin after a single intravenous bolus dose in pigs. Son DS; Ikenoue N; Tagawa Y; Shimoda M; Kokue E J Vet Pharmacol Ther; 2000 Oct; 23(5):311-5. PubMed ID: 11107005 [TBL] [Abstract][Full Text] [Related]
43. Michaelis-Menten metabolite formation kinetics: equations relating area under the curve and metabolite recovery to the administered dose. Chow AT; Jusko WJ J Pharm Sci; 1990 Oct; 79(10):902-6. PubMed ID: 2280360 [TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics of vindesine given as an intravenous bolus and 24-hour infusion in humans. Ohnuma T; Norton L; Andrejczuk A; Holland JF Cancer Res; 1985 Jan; 45(1):464-9. PubMed ID: 3965152 [TBL] [Abstract][Full Text] [Related]
45. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. Yan X; Mager DE; Krzyzanski W J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):25-47. PubMed ID: 20012173 [TBL] [Abstract][Full Text] [Related]
46. Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa. Cojutti PG; Morandin E; Baraldo M; Pea F Int J Antimicrob Agents; 2021 Oct; 58(4):106408. PubMed ID: 34314808 [TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposure. Paccaly A; Frick A; Rohatagi S; Liu J; Shukla U; Rosenburg R; Hinder M; Jensen BK J Clin Pharmacol; 2006 Jan; 46(1):37-44. PubMed ID: 16397282 [TBL] [Abstract][Full Text] [Related]
48. Michaelis-Menten elimination kinetics: areas under curves, steady-state concentrations, and clearances for compartment models with different types of input. Wagner JG; Szpunar GJ; Ferry JJ Biopharm Drug Dispos; 1985; 6(2):177-200. PubMed ID: 4005396 [TBL] [Abstract][Full Text] [Related]
49. Concurrent intravenous administration of a labeled tracer to determine the oral bioavailability of a drug exhibiting Michaelis-Menten metabolism. Rubin GM; Waschek JA; Pond SM; Effeney DJ; Tozer TN J Pharmacokinet Biopharm; 1987 Dec; 15(6):615-31. PubMed ID: 3450845 [TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics of intravenous emulsified isoflurane in beagle dogs. Yang XL; Zhang WS; Liu J; Yang ZB; Jiang XH Br J Anaesth; 2013 Jan; 110(1):128-36. PubMed ID: 23015620 [TBL] [Abstract][Full Text] [Related]
51. The connection between the steady state (Vss) and terminal (Vbeta) volumes of distribution in linear pharmacokinetics and the general proof that Vbeta >/= Vss. Berezhkovskiy LM J Pharm Sci; 2007 Jun; 96(6):1638-52. PubMed ID: 17117429 [TBL] [Abstract][Full Text] [Related]
52. Effect of infusion rate on thiopental dose-response relationships. Assessment of a pharmacokinetic-pharmacodynamic model. Gentry WB; Krejcie TC; Henthorn TK; Shanks CA; Howard KA; Gupta DK; Avram MJ Anesthesiology; 1994 Aug; 81(2):316-24; discussion 25A. PubMed ID: 8053580 [TBL] [Abstract][Full Text] [Related]
53. Michaelis-Menten elimination kinetics of acetate in rabbit. Fujimiya T; Li YJ; Uemura K; Ohbora Y Alcohol Clin Exp Res; 1999 Sep; 23(9):1452-6. PubMed ID: 10512309 [TBL] [Abstract][Full Text] [Related]
55. Exact and approximate solutions for the decades-old Michaelis-Menten equation: Progress-curve analysis through integrated rate equations. Goličnik M Biochem Mol Biol Educ; 2011; 39(2):117-25. PubMed ID: 21445903 [TBL] [Abstract][Full Text] [Related]
56. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling. van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107 [TBL] [Abstract][Full Text] [Related]
57. A simple analytical solution to the three-compartment pharmacokinetic model suitable for computer-controlled infusion pumps. Bailey JM; Shafer SL IEEE Trans Biomed Eng; 1991 Jun; 38(6):522-5. PubMed ID: 1879840 [TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. Retlich S; Duval V; Ring A; Staab A; Hüttner S; Jungnik A; Jaehde U; Dugi KA; Graefe-Mody U Clin Pharmacokinet; 2010 Dec; 49(12):829-40. PubMed ID: 21053992 [TBL] [Abstract][Full Text] [Related]
59. Fundamental pharmacokinetic limits on the utility of using a sinusoidal drug delivery system to enhance therapy. Burnette RR J Pharmacokinet Biopharm; 1992 Oct; 20(5):477-500. PubMed ID: 1287198 [TBL] [Abstract][Full Text] [Related]
60. Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. Gao W; Jusko WJ Drug Metab Dispos; 2012 May; 40(5):990-7. PubMed ID: 22338110 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]